Answer
Limited available data suggest that irinotecan and its metabolite pass into human milk; because of potential adverse reactions in nursing infants, breast-feeding should be discontinued throughout Campto (irinotecan) therapy.
Sources for this answer
- Campto 20mg/ml concentrate for solution for infusion (40mg presentation)Pfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 27Document updated
Sources checked